06/22/22 8:30 AMNasdaq : CYCN clinical trialCyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease FoundationCompany to discuss positive topline and additional clinical data for CY6463 in MELAS patients Mitochondrial disease clinician-researcher, Amel Karaa, M.D., to discuss the potential future impact on patients Webcast scheduled for Tuesday, June 28 th from 8 – 9 a.m. EDT CAMBRIDGE, Mass., June 22,RHEA-AIneutral
06/17/22 8:00 AMNasdaq : CYCN Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial DiseaseRHEA-AIneutral
06/10/22 7:00 AMNasdaq : CYCN clinical trialCyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 SymposiumData from an eight-patient, open-label study demonstrate improvements across multiple biomarkers of mitochondrial function, inflammation, cerebral blood flow, and functional connectivity CY6463 was well tolerated, with no reports of serious adverse events (SAEs) or treatment discontinuation due toRHEA-AIneutral
06/06/22 7:00 AMNasdaq : CYCN conferencesclinical trialCyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 SymposiumCyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stageRHEA-AIneutral
05/04/22 4:01 PMNasdaq : CYCN earningsCyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial ResultsCharacterizing the novel neuropharmacology of CY6463’s NO-sGC-cGMP signal modulation in an integrated clinical strategy currently involving three ongoing, exploratory, biomarker-rich, signal seeking studies: Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) studyRHEA-AIneutral
02/24/22 4:01 PMNasdaq : CYCN Cyclerion Announces CY6463 Clinical Pipeline and Corporate UpdatesPhase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022 Phase 1b study in Cognitive Impairment Associated with Schizophrenia (CIAS) enrollment ongoing; topline data expected in H2 2022 Phase 2a study inRHEA-AIneutral
02/23/22 8:00 AMNasdaq : CYCN Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine CollaborationCyclerion Therapeutics, Inc. (Nasdaq: CYCN) andRHEA-AIpositive
01/26/22 8:00 AMNasdaq : CYCN clinical trialCyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular PathologyCyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitiveRHEA-AIneutral
11/11/21 5:32 PMNasdaq : CYCN conferencesCyclerion Therapeutics to Participate in Jefferies London Healthcare ConferenceCyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that management will attend the Jefferies London Healthcare Conference onRHEA-AIneutral
11/09/21 4:01 PMNasdaq : CYCN earningsCyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate UpdateFirst patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS) Patient screening underway in study in Alzheimer’s disease with vascular pathology (ADv) Enrollment ongoing in study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS);RHEA-AIneutral